{"organizations": [], "uuid": "d99d295389b344a705eb51df27ad2b076dba4978", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-omeros-reaches-agreement-with-fda/brief-omeros-reaches-agreement-with-fda-on-oms721-phase-3-trial-protocol-for-iga-nephropathy-idUSASB0BZJF", "country": "US", "domain_rank": 408, "title": "BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-03T14:14:00.000+02:00", "replies_count": 0, "uuid": "d99d295389b344a705eb51df27ad2b076dba4978"}, "author": "", "url": "https://www.reuters.com/article/brief-omeros-reaches-agreement-with-fda/brief-omeros-reaches-agreement-with-fda-on-oms721-phase-3-trial-protocol-for-iga-nephropathy-idUSASB0BZJF", "ord_in_thread": 0, "title": "BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "ga nephropathy reuters staff  jan", "sentiment": "none"}, {"name": "omeros corp", "sentiment": "none"}, {"name": "omeros corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 16 PM / in 8 minutes BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy Reuters Staff \nJan 3 (Reuters) - Omeros Corp: \n* OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY \n* OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY \n* OMEROS CORP - ‍INITIATES OMS721 PHASE 3 PROGRAM IN HCT-TMA​ \n* OMEROS CORP - ‍ PATIENT ENROLLMENT FOR ITS PHASE 3 CLINICAL TRIAL EVALUATING OMS721 IN PATIENTS WITH IGA NEPHROPATHY IS EXPECTED TO BEGIN EARLY IN FEB Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-03T14:14:00.000+02:00", "crawled": "2018-01-03T14:28:54.000+02:00", "highlightTitle": ""}